One Turn Open the globe →

Health · Beijing, China ·

China approves Eli Lilly's oral weight-loss drug

Reported by 1 outlet · under-reported · first reported Nov 12, 8:01 PM ET

China approved orforglipron, its first oral GLP-1 obesity treatment, ahead of Novo Nordisk.

Why it matters

A pill may widen access to obesity treatment.

Background

GLP-1 drugs have been mostly injections.

The story so far

  1. FDA adds eye risk warning to GLP-1 drugs
  2. FDA orders eye-risk warnings on GLP-1 drugs
  3. China approves Eli Lilly's oral weight-loss drug

Follow the whole story →

Sources

This summary was written automatically from the reporting linked above; follow the sources for the full story. How One Turn works.

See it on the globe →All of Nov 12's stories

More on health